MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) represents a significant discovery in mitochondrial biology. First described by Lee et al. in 2015 in Cell Metabolism, MOTS-c is a 16-amino acid peptide encoded within the mitochondrial 12S ribosomal RNA gene — a location previously thought to contain only ribosomal RNA, not functional protein-coding sequences.
A New Class of Mitochondrial Signals
The discovery of MOTS-c established a new category of signalling molecules: mitochondria-derived peptides (MDPs). The mitochondrial genome, long considered a vestigial structure encoding only 13 proteins, was revealed to harbour additional functional peptide sequences with systemic signalling roles.
Unlike nuclear-encoded proteins, MOTS-c is translated within the mitochondria and can translocate to the cytoplasm and nucleus in response to metabolic stress. This translocation activates AMPK (AMP-activated protein kinase), a master regulator of cellular energy homeostasis.
Metabolic Research Applications
Research in animal models has explored MOTS-c in the context of:
Studies in rodent models have demonstrated that MOTS-c administration improves insulin sensitivity and reduces adiposity, effects attributed to its activation of the AMPK/SIRT1 pathway and subsequent effects on fatty acid oxidation.
Ageing Research
Plasma levels of MOTS-c have been shown to decline with age in human studies, and exercise has been identified as a stimulus for endogenous MOTS-c production. This has positioned MOTS-c as a subject of significant interest in longevity and healthspan research.
For researchers studying mitochondrial function, metabolic disease models, or ageing biology, MOTS-c represents a peptide of exceptional scientific novelty. As with all research peptides, verified purity and proper CoA documentation are essential prerequisites.
For laboratory research only. Not approved for human use.